Pneumocystis jirovecii pneumonia in patients with and without HIV infection: A multicentre comparative study
Raúl Parra-Fariñas1, Moisés Aja Bermúdez2, Carlota Sánchez Benito3
1Infectious Diseases Service, Hospital Universitario Marqués de Valdecilla-IDIVAL, University of Cantabria, Santander, Cantabria, Spain.
Objectives:
To compare the clinical presentation, management and outcomes of microbiologically confirmed Pneumocystis jirovecii pneumonia (PJP) in patients with and without HIV infection.
Methods:
We conducted a multicentre retrospective study of adults admitted to three tertiary hospitals. Patients were stratified by HIV status, and only microbiologically confirmed PJP cases were included. Clinical, radiological, treatment and outcome data were analysed. Multivariable logistic regression identified factors associated with PJP-related mortality and, exploratorily, intensive care unit (ICU) admission.
Results:
Over the 13-year study period, the estimated incidence was 1.40 cases per 100,000 person-years in a catchment population of approximately 780,000 inhabitants. A total of 142 patients were included. Most were HIV-negative (60.6%) and older than those with HIV. Non-HIV patients more often had atypical imaging and required oxygen therapy, whereas ICU admission was more frequent among HIV-positive patients. PJP-related mortality was 10.6%, with no differences by HIV status. In multivariable analysis, ICU admission was independently associated with lower PJP-related mortality (aOR 0.26, 95% confidence interval [CI] 0.07-0.91), while age and HIV status were not. HIV-negative status was independently associated with a lower likelihood of ICU admission compared with PLWH (aOR 0.29, 95% CI 0.11-0.82).
Conclusion:
PJP predominantly affects non-HIV immunocompromised patients. Mortality remains substantial but is not independently associated with HIV status. The association between ICU admission and mortality likely reflects selection and survivorship bias, highlighting the need for improved prophylaxis and diagnostic vigilance.
Related Concept Videos
01:30Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
01:29Pneumonia II: Pathophysiology
01:30Pneumonia III: Complications and Assessment
01:28Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:30Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
01:24Chronic Obstructive Pulmonary Disease
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...